{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:17:45Z","timestamp":1768454265526,"version":"3.49.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.semcancer.2019.08.024","type":"journal-article","created":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T16:48:57Z","timestamp":1566406137000},"page":"283-289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["The adjuvant treatment revolution for high-risk melanoma patients"],"prefix":"10.1016","volume":"59","author":[{"given":"Francesco","family":"Spagnolo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Boutros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrica","family":"Tanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Queirolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.semcancer.2019.08.024_bib0005","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual: melanoma Staging: AJCC 8 th Edition","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J. Clin."},{"issue":"18_suppl","key":"10.1016\/j.semcancer.2019.08.024_bib0010","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.18_suppl.lba9002","article-title":"Survival of SLNB-positive melanoma patients with and without complete lymph node dissection: a multicenter, randomized DECOG trial","volume":"33","author":"Leiter","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.semcancer.2019.08.024_bib0015","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","article-title":"Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial","volume":"17","author":"Leiter","year":"2016","journal-title":"Lancet Oncol."},{"issue":"23","key":"10.1016\/j.semcancer.2019.08.024_bib0020","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.semcancer.2019.08.024_bib0025","first-page":"93","article-title":"The Eighth Edition AJCC Cancer staging Manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J. Clin."},{"issue":"7","key":"10.1016\/j.semcancer.2019.08.024_bib0030","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1310460","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma","volume":"370","author":"Morton","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2019.08.024_bib0035","unstructured":"JF Thompson, LE Haydu, RF Uren et al. Preoperative Ultrasound Assessment of Regional Lymph Nodes in Melanoma Patients Does not Provide Reliable Nodal Staging: Results from a Large Multicenter Trial. Ann. Surg. 9000."},{"issue":"15_suppl","key":"10.1016\/j.semcancer.2019.08.024_bib0040","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.9501","article-title":"Final analysis of DECOG-SLT trial: survival outcomes of complete lymph node dissection in melanoma patients with positive sentinel node","volume":"36","author":"Leiter","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.semcancer.2019.08.024_bib0045","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/SLA.0b013e31818fefe0","article-title":"Sentinel node tumor burden according to the rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes","volume":"248","author":"van Akkooi","year":"2008","journal-title":"Ann. Surg."},{"issue":"23","key":"10.1016\/j.semcancer.2019.08.024_bib0050","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1056\/NEJMe1704290","article-title":"The enigma of regional lymph nodes in melanoma","volume":"376","author":"Coit","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.semcancer.2019.08.024_bib0055","doi-asserted-by":"crossref","first-page":"367","DOI":"10.6004\/jnccn.2019.0018","article-title":"Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Coit","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw. J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.semcancer.2019.08.024_bib0060","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J. Clin. Oncol."},{"issue":"9120","key":"10.1016\/j.semcancer.2019.08.024_bib0065","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(97)12445-X","article-title":"Randomised trial of interferon \u03b1-2a as adjuvant therapy in resected primary melanoma thicker than 1\u00b75 mm without clinically detectable node metastases","volume":"351","author":"Grob","year":"1998","journal-title":"Lancet"},{"issue":"9633","key":"10.1016\/j.semcancer.2019.08.024_bib0070","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)61033-8","article-title":"Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial","volume":"372","author":"Eggermont","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.semcancer.2019.08.024_bib0075","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008955.pub2","article-title":"Interferon alpha for the adjuvant treatment of cutaneous melanoma","author":"Mocellin","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.semcancer.2019.08.024_bib0080","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2017.06.006","article-title":"Adjuvant interferon-\u03b1 for the treatment of high-risk melanoma: an individual patient data meta-analysis","volume":"82","author":"Ives","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.semcancer.2019.08.024_bib0085","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1093\/annonc\/mdy229","article-title":"Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial","volume":"29","author":"Corrie","year":"2018","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol"},{"issue":"5","key":"10.1016\/j.semcancer.2019.08.024_bib0090","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000203","article-title":"Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I\/II study with a first assessment of a predictive gene signature","volume":"2","author":"Grob","year":"2017","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.semcancer.2019.08.024_bib0095","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol."},{"issue":"19","key":"10.1016\/j.semcancer.2019.08.024_bib0100","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"15_suppl","key":"10.1016\/j.semcancer.2019.08.024_bib0105","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9500","article-title":"A phase III randomized study of adjuvant ipilimumab (3 or 10 mg\/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): preliminary safety and efficacy of the ipilimumab arms","volume":"35","author":"Tarhini","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.semcancer.2019.08.024_bib0110","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.9504","article-title":"United States Intergroup E1609: a phase III randomized study of adjuvant ipilimumab (3 or 10 mg\/kg) versus high-dose interferon-\u03b12b for resected high-risk melanoma","volume":"37","author":"Tarhini","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2019.08.024_bib0115","doi-asserted-by":"crossref","unstructured":"C Robert, A Ribas, J Schachter et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol doi:10.1016\/S1470-2045(19)30388-2.","DOI":"10.1016\/S1470-2045(19)30388-2"},{"issue":"11","key":"10.1016\/j.semcancer.2019.08.024_bib0120","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol."},{"issue":"19","key":"10.1016\/j.semcancer.2019.08.024_bib0125","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"15_suppl","key":"10.1016\/j.semcancer.2019.08.024_bib0130","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.9502","article-title":"Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III\/IV melanoma: updated results from a phase III trial (CheckMate 238)","volume":"36","author":"Weber","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.semcancer.2019.08.024_bib0135","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1056\/NEJMc1807505","article-title":"A. Adjuvant pembrolizumab in resected stage III melanoma","volume":"379","author":"Eggermont","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.semcancer.2019.08.024_bib0140","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/jnci\/djx133","article-title":"Relapse-free survival as a surrogate for overall survival in the evaluation of stage II\u2013III melanoma adjuvant therapy","volume":"110","author":"Suciu","year":"2017","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.semcancer.2019.08.024_bib0145","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.semcancer.2019.08.024_bib0150","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol."},{"issue":"9839","key":"10.1016\/j.semcancer.2019.08.024_bib0155","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.semcancer.2019.08.024_bib0160","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","author":"Robert","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.semcancer.2019.08.024_bib0165","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.semcancer.2019.08.024_bib0170","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2019.08.024_bib0175","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S1470-2045(18)30106-2","article-title":"Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"19","author":"Maio","year":"2018","journal-title":"Lancet Oncol."},{"issue":"19","key":"10.1016\/j.semcancer.2019.08.024_bib0180","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant Dabrafenib plus Trametinib in Stage IIIBRAF -Mutated Melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2019.08.024_bib0185","first-page":"JCO1801219","article-title":"Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-Mutant stage III melanoma","author":"Hauschild","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"9992","key":"10.1016\/j.semcancer.2019.08.024_bib0190","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet Lond. Engl"},{"issue":"1","key":"10.1016\/j.semcancer.2019.08.024_bib0195","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"15_suppl","key":"10.1016\/j.semcancer.2019.08.024_bib0200","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.9590","article-title":"Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF-mutant melanoma","volume":"36","author":"Schadendorf","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.semcancer.2019.08.024_bib0205","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol"},{"key":"10.1016\/j.semcancer.2019.08.024_bib0210","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw435.37","article-title":"Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E\/K\u2013mutant cutaneous melanoma","author":"Robert","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.semcancer.2019.08.024_bib0215","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejca.2018.02.022","article-title":"Risk stratification of sentinel node\u2013positive melanoma patients defines surgical management and adjuvant therapy treatment considerations","volume":"96","author":"Verver","year":"2018","journal-title":"Eur. J. Cancer"},{"issue":"36","key":"10.1016\/j.semcancer.2019.08.024_bib0220","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol"},{"issue":"11","key":"10.1016\/j.semcancer.2019.08.024_bib0225","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.semcancer.2019.08.024_bib0230","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","article-title":"Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma","volume":"24","author":"Amaria","year":"2018","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.semcancer.2019.08.024_bib0235","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Rozeman","year":"2019","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2019.08.024_bib0240","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(18)30015-9","article-title":"Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial","volume":"19","author":"Amaria","year":"2018","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.semcancer.2019.08.024_bib0245","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S1470-2045(19)30331-6","article-title":"Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB\u2013C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.semcancer.2019.08.024_bib0250","doi-asserted-by":"crossref","first-page":"e378","DOI":"10.1016\/S1470-2045(19)30332-8","article-title":"Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium","volume":"20","author":"Amaria","year":"2019","journal-title":"Lancet Oncol."}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X19301105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X19301105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:35:52Z","timestamp":1760916952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X19301105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":50,"alternative-id":["S1044579X19301105"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2019.08.024","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The adjuvant treatment revolution for high-risk melanoma patients","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2019.08.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}